The purpose of this study is to evaluate the retention in tumour and distribution behavior of \[Lu-177\]-Catalase after intratumoral injection,and preliminary evaluation the efficacy and safety of \[Lu-177\]-Catalase.
Male or female patients, aged 18-70 years; ECOG score 0 or 1;
Patients with advanced malignant tumors, such as liver cancer, ovarian cancer, prostate cancer, and so on, clearly diagnosed by pathology and/or cytology;
Patients with advanced solid tumors who have failed or cannot tolerate standard treatment;
Expected survival of more than 3 months;
Severe abnormal liver and kidney function;
Pregnant, pregnant and lactating women;
Can not lie flat for half an hour;
Refuse to join the clinical investigator;